Literature DB >> 16081796

Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes.

Beatrix Kotlan1, Peter Simsa, Jean-Luc Teillaud, Wolf Herman Fridman, Jozsef Toth, Michael McKnight, Mark C Glassy.   

Abstract

The potential tumor-recognizing capacity of B cells infiltrating human breast carcinoma is an important aspect of breast cancer biology. As an experimental system, we used human medullary breast carcinoma because of its heavy B lymphocytic infiltration paralleled to a relatively better prognosis. Ig-rearranged V region V(H)-J(H), Vkappa-Jkappa, and Vlambda-Jlambda genes, amplified by RT-PCR of the infiltrating B cells, were cloned, sequenced, and subjected to a comparative DNA analysis. A combinatorial single-chain variable fragment Ab minilibrary was constructed out of randomly selected V(H) and Vkappa clones and tested for binding activity. Our data analysis revealed that some of the V(H)-J(H), Vkappa-Jkappa, and Vlambda-Jlambda region sequences were being assigned to clusters with oligoclonal predominance, while other characteristics of the Ab repertoire were defined also. A tumor-restricted binder clone could be selected out of the single-chain variable fragment kappa minilibrary tested against membrane fractions of primary breast tumor cells and tumor cell lines, the V(H) of which proved to be the overexpressed V(H)3-1 cluster. The specific binding was confirmed by FACS analysis with primary breast carcinoma cells and MDA-MB 231 cell line. ELISA and thin layer chromatography dot-blot experiments showed this target Ag to be a ganglioside D3 (GD3). Our results are a proof of principle about the capacity of B cells infiltrating breast carcinomas to reveal key cancer-related Ags, such as the GD3. GD3-specific Abs may influence tumor cell progression and could be used for further development of diagnostic and/or therapeutic purposes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16081796     DOI: 10.4049/jimmunol.175.4.2278

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Identification of tumor-associated antigens from medullary breast carcinoma by a modified SEREX approach.

Authors:  Ramziya Kiyamova; Olga Kostianets; Sergey Malyuchik; Valeriy Filonenko; Vasiliy Usenko; Vadym Gurtovyy; Yuliya Khozayenko; Stepan Antonuk; Lloyd Old; Ivan Gout
Journal:  Mol Biotechnol       Date:  2010-10       Impact factor: 2.695

2.  Tumor-infiltrating B cell immunoglobulin variable region gene usage in invasive ductal breast carcinoma.

Authors:  Peter Simsa; Jean-Luc Teillaud; David I Stott; József Tóth; Beatrix Kotlan
Journal:  Pathol Oncol Res       Date:  2005-07-01       Impact factor: 3.201

3.  Antigen-Presenting Intratumoral B Cells Affect CD4+ TIL Phenotypes in Non-Small Cell Lung Cancer Patients.

Authors:  Tullia C Bruno; Peggy J Ebner; Brandon L Moore; Olivia G Squalls; Katherine A Waugh; Evgeniy B Eruslanov; Sunil Singhal; John D Mitchell; Wilbur A Franklin; Daniel T Merrick; Martin D McCarter; Brent E Palmer; Jeffrey A Kern; Jill E Slansky
Journal:  Cancer Immunol Res       Date:  2017-08-28       Impact factor: 11.151

4.  B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma.

Authors:  Marianela Candolfi; James F Curtin; Kader Yagiz; Hikmat Assi; Mia K Wibowo; Gabrielle E Alzadeh; David Foulad; A K M G Muhammad; Sofia Salehi; Naomi Keech; Mariana Puntel; Chunyan Liu; Nicholas R Sanderson; Kurt M Kroeger; Robert Dunn; Gislaine Martins; Pedro R Lowenstein; Maria G Castro
Journal:  Neoplasia       Date:  2011-10       Impact factor: 5.715

5.  Tumor-infiltrating B cells come into vogue.

Authors:  Michael Linnebacher
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

6.  The novel panel assay to define tumor-associated antigen-binding antibodies in patients with metastatic melanomas may have diagnostic value.

Authors:  Beatrix Kotlan; Gabriella Liszkay; Miri Blank; Orsolya Csuka; Timea Balatoni; Laszlo Toth; Klara Eles; Szabolcs Horvath; Gyorgy Naszados; Judit Olasz; Balazs Banky; Jozsef Toth; Maria Godeny; Francesco M Marincola; Miklos Kasler; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

7.  Possible significance of differences in proportions of cytotoxic T cells and B-lineage cells in the tumour-infiltrating lymphocytes of typical and atypical medullary carcinomas of the breast.

Authors:  Kok Haw Jonathan Lim; Premasiri Upali Telisinghe; Muhd Syafiq Abdullah; Ranjan Ramasamy
Journal:  Cancer Immun       Date:  2010-01-22

8.  The immune microenvironment of human tumors: general significance and clinical impact.

Authors:  Wolf-Herman Fridman; Marie-Caroline Dieu-Nosjean; Franck Pagès; Isabelle Cremer; Diane Damotte; Catherine Sautès-Fridman; Jérôme Galon
Journal:  Cancer Microenviron       Date:  2012-10-30

9.  A 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancer.

Authors:  S Hernández-Prieto; A Romera; M Ferrer; J L Subiza; J A López-Asenjo; J R Jarabo; A M Gómez; Elena M Molina; J Puente; J L González-Larriba; F Hernando; B Pérez-Villamil; E Díaz-Rubio; J Sanz-Ortega
Journal:  Clin Transl Oncol       Date:  2014-10-10       Impact factor: 3.405

10.  Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.

Authors:  Katy Milne; Martin Köbel; Steven E Kalloger; Rebecca O Barnes; Dongxia Gao; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.